Cardinal Health (NYSE:CAH) Releases Earnings Results, Beats Estimates By $0.13 EPS

Cardinal Health (NYSE:CAH) posted its quarterly earnings results on Thursday. The company reported $2.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.13, Briefing.com reports. Cardinal Health had a net margin of 0.25% and a negative return on equity of 54.74%. The business had revenue of $54.90 billion during the quarter, compared to the consensus estimate of $56.05 billion. During the same quarter last year, the firm posted $1.74 EPS. Cardinal Health’s revenue was up 8.7% compared to the same quarter last year. Cardinal Health updated its FY24 guidance to $7.30-7.40 EPS and its FY25 guidance to at least $7.50 EPS.

Cardinal Health Trading Down 4.0 %

Shares of NYSE CAH traded down $4.07 during midday trading on Friday, hitting $98.91. The company’s stock had a trading volume of 3,446,183 shares, compared to its average volume of 2,028,678. The stock has a fifty day moving average price of $109.10 and a 200 day moving average price of $105.01. The firm has a market capitalization of $24.06 billion, a price-to-earnings ratio of 43.96, a P/E/G ratio of 1.03 and a beta of 0.71. Cardinal Health has a one year low of $77.56 and a one year high of $116.04.

Cardinal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were given a dividend of $0.5006 per share. The ex-dividend date of this dividend was Thursday, March 28th. This represents a $2.00 dividend on an annualized basis and a yield of 2.02%. Cardinal Health’s dividend payout ratio is presently 88.89%.

Analysts Set New Price Targets

CAH has been the subject of a number of analyst reports. Argus upgraded shares of Cardinal Health from a “hold” rating to a “buy” rating in a report on Friday, February 9th. Wells Fargo & Company decreased their price objective on Cardinal Health from $96.00 to $94.00 and set an “underweight” rating for the company in a report on Monday, April 29th. UBS Group raised their target price on Cardinal Health from $122.00 to $125.00 and gave the company a “buy” rating in a report on Monday, February 5th. Robert W. Baird decreased their price target on Cardinal Health from $134.00 to $128.00 and set an “outperform” rating for the company in a report on Friday. Finally, StockNews.com upgraded Cardinal Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Cardinal Health has a consensus rating of “Moderate Buy” and a consensus target price of $105.79.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.